In:
Arteriosclerosis, Thrombosis, and Vascular Biology, Ovid Technologies (Wolters Kluwer Health), Vol. 30, No. 3 ( 2010-03), p. 403-410
Abstract:
A novel platelet-specific MRI contrast agent (P975) targeting the glycoprotein α IIb β 3 was applied for molecular MRI of inflammatory thrombi in a mouse model. Several control experiments and a competitive inhibition experiment revealed the specificity of P975 and suggest its potential for noninvasive imaging of vulnerable or high-risk atherosclerotic plaques.
Type of Medium:
Online Resource
ISSN:
1079-5642
,
1524-4636
DOI:
10.1161/ATVBAHA.109.198556
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2010
detail.hit.zdb_id:
1494427-3